Choose from nearly 1,000 secondary antibodies conjugated to more than 40 different enzymatic, fluorescent, or biotin labels. Use the filters on the left to sort our secondary antibodies by species, application, host, or conjugate.
To learn more about secondary antibodies, download and read our Secondary Antibody Handbook for technical information and tips to guide you when choosing a secondary antibody for your experiment.
To understand more about direct vs. indirect detection, including benefits of a secondary antibody and when to use one, please read our resources on Direct vs. Indirect Detection Methods.
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF007 | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alkaline Phosphatase | NB7157 | |||
| Allophycocyanin | NB7156APC | |||
| Biotin | NB7158 | |||
| DyLight 350 | NB7156UV | |||
| DyLight 405 | NB7156V | |||
| DyLight 488 | NB7156G | |||
| DyLight 550 | NB7156R | |||
| DyLight 594 | NB7156DL594 | |||
| DyLight 650 | NB7156C | |||
| DyLight 680 | NB7156FR | |||
| DyLight 755 | NB7156IR | |||
| FITC | NB7159 | |||
| PE | NB7156PE | |||
| PerCP | NB7156PCP | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alkaline Phosphatase | NB7157 | |||
| Allophycocyanin | NB7156APC | |||
| Biotin | NB7158 | |||
| DyLight 350 | NB7156UV | |||
| DyLight 405 | NB7156V | |||
| DyLight 488 | NB7156G | |||
| DyLight 550 | NB7156R | |||
| DyLight 594 | NB7156DL594 | |||
| DyLight 650 | NB7156C | |||
| DyLight 680 | NB7156FR | |||
| DyLight 755 | NB7156IR | |||
| FITC | NB7159 | |||
| HRP | NB7160 | |||
| PE | NB7156PE | |||
| PerCP | NB7156PCP | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alkaline Phosphatase | NB7536 | |||
| Allophycocyanin | NB7535APC | |||
| Biotin | NB7537 | |||
| DyLight 350 | NB7535UV | |||
| DyLight 405 | NB7535V | |||
| DyLight 488 | NB7535G | |||
| DyLight 550 | NB7535R | |||
| DyLight 594 | NB7535DL594 | |||
| DyLight 650 | NB7535C | |||
| DyLight 680 | NB7535FR | |||
| DyLight 755 | NB7535IR | |||
| FITC | NB7538 | |||
| HRP | NB7539 | |||
| PE | NB7535PE | |||
| PerCP | NB7535PCP | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alkaline Phosphatase | NB7277-0.5mg | |||
| Allophycocyanin | NB7276APC | |||
| Biotin | NB7276B | |||
| DyLight 350 | NB7276UV | |||
| DyLight 405 | NB7276V | |||
| DyLight 488 | NB7276G | |||
| DyLight 550 | NB7276R | |||
| DyLight 594 | NB7276DL594 | |||
| DyLight 650 | NB7276C | |||
| DyLight 680 | NB7276FR | |||
| DyLight 755 | NB7276IR | |||
| FITC | NB7278 | |||
| HRP | NB7279 | |||
| PE | NB7276PE | |||
| PerCP | NB7276PCP | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Biotin | BAF018 | |||
| HRP (Horseradish Peroxidase) | HAF018 | |||
| NL493 | NL009 | |||
| NL637 | NL008 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | HAF018 | |||
| Carrier Free | D-201-C-ABS2 | |||
| Carrier Free | NL008 | |||
| Carrier Free | NL009 | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alkaline Phosphatase | NB7447 | |||
| Allophycocyanin | NB7446APC | |||
| Biotin | NB7446B | |||
| DyLight 350 | NB7446UV | |||
| DyLight 405 | NB7446V | |||
| DyLight 488 | NB7446G | |||
| DyLight 550 | NB7446R | |||
| DyLight 594 | NB7446DL594 | |||
| DyLight 650 | NB7446C | |||
| DyLight 680 | NB7446FR | |||
| DyLight 755 | NB7446IR | |||
| FITC | NB7448 | |||
| HRP | NB7449 | |||
| PE | NB7446PE | |||
| PerCP | NB7446PCP | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alkaline Phosphatase | NB7509 | |||
| Allophycocyanin | NB7508APC | |||
| Biotin | NBP1-69914B | |||
| DyLight 350 | NB7508UV | |||
| DyLight 405 | NB7508V | |||
| DyLight 488 | NB7508G | |||
| DyLight 550 | NB7508R | |||
| DyLight 594 | NB7508DL594 | |||
| DyLight 650 | NB7508C | |||
| DyLight 680 | NB7508FR | |||
| DyLight 755 | NB7508IR | |||
| FITC | NB7510 | |||
| HRP | NB7511 | |||
| PE | NB7508PE | |||
| PerCP | NB7508PCP | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Allophycocyanin | NB7343APC | |||
| Biotin | NB7343B | |||
| DyLight 350 | NB7343UV | |||
| DyLight 405 | NB7343V | |||
| DyLight 488 | NB7343G | |||
| DyLight 550 | NB7343R | |||
| DyLight 594 | NB7343DL594 | |||
| DyLight 650 | NB7343C | |||
| DyLight 680 | NB7343FR | |||
| DyLight 755 | NB7343IR | |||
| FITC | NB7345 | |||
| HRP | NB7346 | |||
| PE | NB7343PE | |||
| PerCP | NB7343PCP | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Allophycocyanin | NB7240APC | |||
| Biotin | NB7240B | |||
| DyLight 350 | NB7240UV | |||
| DyLight 405 | NB7240V | |||
| DyLight 488 | NB7240G | |||
| DyLight 550 | NB7240R | |||
| DyLight 594 | NB7240DL594 | |||
| DyLight 650 | NB7240C | |||
| DyLight 680 | NB7240FR | |||
| DyLight 755 | NB7240IR | |||
| FITC | NB7241 | |||
| HRP | NB7242 | |||
| PE | NB7240PE | |||
| PerCP | NB7240PCP | |||
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33738242).](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33738242).")
![Flow Cytometry: Goat anti-Rabbit IgG (H+L) Secondary Antibody [NB7156] - Both samples are cultured mouse microglial cells. The red is stained cells while the grey are cells with no primary antibody added (but the secondary antibody is present). Flow cytometry image submitted by a verified customer review.. Using the FITC format of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-Flow-Cytometry-NB7156-img0001.jpg "Flow Cytometry: Goat anti-Rabbit IgG (H+L) Secondary Antibody [NB7156] - Both samples are cultured mouse microglial cells. The red is stained cells while the grey are cells with no primary antibody added (but the secondary antibody is present). Flow cytometry image submitted by a verified customer review.. Using the FITC format of this antibody.")
![Western Blot: Goat anti-Mouse IgG (H+L) Secondary Antibody [NB7535] - Image using the HRP format of Goat anti-Mouse IgG (H+L) Secondary Antibody.](http://images.novusbio.com/fullsize/Goat-anti-Mouse-IgG-H+L-Secondary-Antibody-Western-Blot-NB7535-img0010.jpg "Western Blot: Goat anti-Mouse IgG (H+L) Secondary Antibody [NB7535] - Image using the HRP format of Goat anti-Mouse IgG (H+L) Secondary Antibody.")
![Immunocytochemistry/Immunofluorescence: Goat anti-Mouse IgG (H+L) Secondary Antibody [NB7535] - Detection of RYK in human primary colon cancer cell line using anti-RYK antibody followed by Goat anti-Mouse IgG (H+L) Secondary Antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/Goat-anti-Mouse-IgG-H+L-Secondary-Antibody-Immunocytochemistry-Immunofluorescence-NB7535-img0008.jpg)
![Immunohistochemistry-Paraffin: Goat anti-Mouse IgG (H+L) Secondary Antibody [NB7535] - FFPE serial sections of human stomach carcinoma. Primary Antibody: Mouse anti-p53 (Clone DO-1) used at a dilution of 1:100. Secondary Antibody Goat anti-Mouse IgG (H+L) Secondary Antibody used at a dilution of 1:200 (5ug/ml). Detection: DAB. Image using the HRP format of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Mouse-IgG-H+L-Secondary-Antibody-Immunohistochemistry-Paraffin-NB7535-img0009.jpg)
![Flow Cytometry: Goat anti-Mouse IgG (H+L) Secondary Antibody [NB7535] - Detection of RYK in human primary colon cancer cell line using anti-RYK antibody followed by goat anti-mouse IgG FITC conjugated secondary antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/Goat-anti-Mouse-IgG-H+L-Secondary-Antibody-Flow-Cytometry-NB7535-img0002.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody (Pre-adsorbed) [NBP1-72732] - Lane 1: Rabbit IgG whole molecule. Lane 2: Rabbit IgG F(ab) Fragment. Lane 3: Rabbit IgG F(c) Fragment. Lane 4: Rabbit IgM Whole Molecule. Lane 5: Normal Rabbit Serum. All samples were reduced. Load: 50 ng per lane. Block: incubated with blocking buffer for 30 min at RT. Primary Antibody: Anti-Rabbit IgG (H&L) (GOAT) Antibody 1:1,000 for 60 min at RT. Secondary antibody: Anti-Goat IgG (DONKEY) Peroxidase Conjugated Antibody 1:40,000 in incubated with blocking buffer for 30 min at RT. Predicted/Observed Size: 25 and 50 kDa for Rabbit IgG and Serum, 25 kDa for F(c) and F(ab), 70 and 23 kDa for IgM. Rabbit F(c) migrates slightly higher. Image from the Alkaline Phosphatase version of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-Pre-adsorbed-Western-Blot-NBP1-72732-img0021.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody (Pre-adsorbed) [NBP1-72732] - Lane 1: Rabbit IgG whole molecule. Lane 2: Rabbit IgG F(ab) Fragment. Lane 3: Rabbit IgG F(c) Fragment. Lane 4: Rabbit IgM Whole Molecule. Lane 5: Normal Rabbit Serum. All samples were reduced. Load: 50 ng per lane. Block: incubated with blocking buffer for 30 min at RT. Primary Antibody: Anti-Rabbit IgG (H&L) (GOAT) Antibody 1:1,000 for 60 min at RT. Secondary antibody: Anti-Goat IgG (DONKEY) Peroxidase Conjugated Antibody 1:40,000 in incubated with blocking buffer for 30 min at RT. Predicted/Observed Size: 25 and 50 kDa for Rabbit IgG and Serum, 25 kDa for F(c) and F(ab), 70 and 23 kDa for IgM. Rabbit F(c) migrates slightly higher. Image from the Alkaline Phosphatase version of this antibody.")
![Immunocytochemistry/Immunofluorescence: Goat anti-Rabbit IgG (H+L) Secondary Antibody (Pre-adsorbed) [NBP1-72732] - DyLight 488 conjugated anti-Rabbit IgG was used to demonstrate 2 color STED immunofluorescence microscopy. Methanol fixed A431 cells were blocked with normal goat serum. The cells were then probed with 0.4 ug/mL final concentration of anti-HDAC and detected with 0.2 ug/mL DyLight488 conjugated Anti-RABBIT IgG [GOAT] secondary antibody (colored GREEN). Also shown in this 2-color STED image is a-tubulin monoclonal antibody [MOUSE] detected with ATTO 425 conjugated anti-MOUSE IgG [GOAT] secondary antibody (colored RED). Image from the DyLight 488 version of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-Pre-adsorbed-Immunocytochemistry-Immunofluorescence-NBP1-72732-img0019.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody (Pre-adsorbed) [NBP1-72732] - Lane 1: Rabbit IgG. Load: 100 ng per lane. Primary antibody: RABBIT IgG (H&L) Antibody Pre-adsorbed at 1:1,000 for overnight at 4C. Secondary antibody: DyLight 800 goat secondary antibody 1:20,000 for 30 min at RT. Block: incubated with blocking buffer for 30 min at RT. Predicted/Observed size: 55 and 28 kDa for Rabbit IgG.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-Pre-adsorbed-Western-Blot-NBP1-72732-img0007.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody (Pre-adsorbed) [NBP1-72732] - Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [Rhodamine] [NB7575] - Lane 1: Rabbit IgG. Load: 50 ng per lane. Primary antibody: None. Secondary antibody: Rhodamine goat secondary antibody at 1:1,000 for 60 min at RT. Block: incubated with blocking buffer for 30 min at RT. Predicted/Observed size: 25 & 55 kDa for Rabbit IgG.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-Pre-adsorbed-Western-Blot-NBP1-72732-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: Goat anti-Rabbit IgG (H+L) Secondary Antibody (Pre-adsorbed) [NBP1-72732] - Image from the DyLight 488 version of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-Pre-adsorbed-Immunocytochemistry-Immunofluorescence-NBP1-72732-img0018.jpg)
![Fluorophore-linked immunosorbent assay: Goat anti-Rabbit IgG (H+L) Secondary Antibody (Pre-adsorbed) [NBP1-72732] - Using the DyLight 405 format of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-Pre-adsorbed-Fluorophore-linked-immunosorbent-assay-NBP1-72732-img0026.jpg)
![SDS-Page: Goat anti-Rabbit IgG (H+L) Secondary Antibody (Pre-adsorbed) [NBP1-72732] - SDS-Page of Goat anti-Rabbit IgG (H+L) Secondary Antibody [Unconjugated] (Pre-adsorbed).Lane 1: Goat anti-Rabbit IgG - Non-Reduced.Lane 2: Goat anti-Rabbit IgG - Reduced.Load: 1.0 ug per lane.Predicted/Observed size: 25 & 55 kDa - Reduced, 160 kDa - Non-Reduced for Goat IgG.Other Band(s): None.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-Pre-adsorbed-SDS-Page-NBP1-72732-img0025.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - A) Kidney from control did not show any specific staining in the glomeruli. Only erythrocytes (arrow) showed weak fluorescence. B) 1 day: endothelium & material within the capillaries of a glomerulus were highly fluorescent (white arrow). In an adjacent glomerulus, only the endothelium was stained (white arrowhead) not for the lumina of the vessels (black arrow). C) Erythrocytes (arrowhead) and endothelium (arrow). D) 7 days: fluorescence within the capillaries (arrowhead) & endothelium was weaker. E) 1 day after ranibizumab injection, the endothelium cell layer (white arrow) and erythrocytes (arrowhead and black arrow) were fluorescent. F) The fluorescence (arrowhead) was nearly lost 7 days after injection. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0113701) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-Fc-fragment-Secondary-Antibody-Immunohistochemistry-NB7446-img0002.jpg "Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - A) Kidney from control did not show any specific staining in the glomeruli. Only erythrocytes (arrow) showed weak fluorescence. B) 1 day: endothelium & material within the capillaries of a glomerulus were highly fluorescent (white arrow). In an adjacent glomerulus, only the endothelium was stained (white arrowhead) not for the lumina of the vessels (black arrow). C) Erythrocytes (arrowhead) and endothelium (arrow). D) 7 days: fluorescence within the capillaries (arrowhead) & endothelium was weaker. E) 1 day after ranibizumab injection, the endothelium cell layer (white arrow) and erythrocytes (arrowhead and black arrow) were fluorescent. F) The fluorescence (arrowhead) was nearly lost 7 days after injection. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0113701) licensed under a CC-BY license.")
![Western Blot: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Image from verified customer review. Image using the HRP form of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-Fc-Secondary-Antibody-Western-Blot-NB7446-img0001.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416154644.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416165644.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416154630.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416175295.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416163732.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416171447.jpg)
![ELISA: Goat anti-Canine IgE Heavy Chain Secondary Antibody [NB7343] - Sandwich ELISA for total dog IgE measurement showing standard curve at 2 different coating antibody concentrations. Coating: 1ug/ml in carbonate buffer, pH 9.6. Standard: purified dog IgE, range: 156pg/ml to 15.000 pg/ml. Detection with secondary antibody (HRP-labeled) and TMB substrate. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/Goat-anti-Canine-IgE-Secondary-Antibody-ELISA-NB7343-img0001.jpg "ELISA: Goat anti-Canine IgE Heavy Chain Secondary Antibody [NB7343] - Sandwich ELISA for total dog IgE measurement showing standard curve at 2 different coating antibody concentrations. Coating: 1ug/ml in carbonate buffer, pH 9.6. Standard: purified dog IgE, range: 156pg/ml to 15.000 pg/ml. Detection with secondary antibody (HRP-labeled) and TMB substrate. This image was submitted via customer Review.")
![Dot Blot: Goat anti-Canine IgE Secondary Antibody [NB7343] - D.p. extracts have effects on MCs though the IgE-FcepsilonRI axis. SDS-PAGE of recombinants (300 ng) and Western blotting (168.8 ng, for rDer p 15; 143.8 ng of rDer p 18 per gel lane) of specific IgE in canine sera. Image collected and cropped by CiteAb from the following publication (//waojournal.biomedcentral.com/articles/10.1186/s40413-017-0154-3), licensed under a CC-BY license.. Using the HRP format of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Canine-IgE-Secondary-Antibody-Dot-Blot-NB7343-img0002.jpg)